Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atrium divests chemicals division

This article was originally published in The Tan Sheet

Executive Summary

Health and nutrition product marketer Atrium has completed the sale of its active ingredients and specialty chemicals division to Unipex Group for $166.4 million in cash, "subject to post-closing working capital adjustment," the company announces May 22. Proceeds will provide the firm better financial flexibility to pursue its corporate strategy, the Quebec City, Canada-based company notes. With the sale, Atrium has reached its goal of focusing entirely on health and nutrition products (1"The Tan Sheet" Jan. 6, 2008, In Brief)...

You may also be interested in...



Atrium re-evaluates business

In an effort to better position itself as a leader in the health and nutritional products arena, Atrium Innovations is considering a sale of its active ingredients and specialty chemicals division, the Canadian nutritional products marketer announces Dec. 18. A sale of the division would "strengthen Atrium with a targeted vision and development strategy in the high potential nutritional supplements market," the Quebec-based firm says, noting it plans to act as a consolidator in the fragmented segment. Atrium strengthened its health division with the purchase of German-based Mucos in July and was recently granted permission to sell Mucos' enzyme-based supplement Wobenzym N in the U.S. (1"The Tan Sheet" Nov. 26, 2007, In Brief)...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS101709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel